Humanized Antibody Amino Acid Modifications for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current humanized monoclonal antibodies for cancer and immunodeficiency disorders lack specific site-specific amino acid modifications, which limits their bioactivity, stability, and immunogenicity, and does not effectively target tumor cells or immune-functioning cells to modulate the immune response.
Innovation Solution
Development of mutated humanized monoclonal antibodies with site-specific amino acid modifications, such as substitutions and deletions, in the light and heavy chain variable regions, to enhance bioactivity, stability, and reduce immunogenicity, while maintaining immunomodulatory activity and binding capabilities to B lymphoblastoid cells and peripheral blood lymphocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If humanized monoclonal antibodies are developed based on murine BAT, then immunomodulatory activity is improved, but bioactivity and stability are limited due to lack of site-specific amino acid modifications
Solution Approach 1:
The patent applies parameter changes by introducing site-specific amino acid modifications at precisely defined positions in the variable regions of the humanized monoclonal antibodies. These modifications alter the biochemical parameters of the antibody structure, thereby enhancing bioactivity and stability while maintaining immunomodulatory function.
Solution Approach 2:
The invention implements local quality by making specific amino acid substitutions at particular positions (e.g., positions 2, 30, 69, 77, 97, 98 in light chain and positions 35, 69, 70, 71 in heavy chain) rather than uniform modifications throughout the structure. This localized approach optimizes specific functional regions while preserving overall antibody integrity.
2Reliability
If humanized monoclonal antibodies are developed based on murine BAT, then immunomodulatory activity is improved, but immunogenicity is reduced effectiveness
Solution Approach 1:
The patent utilizes parameter changes by introducing specific amino acid modifications that alter the immunogenic properties of the humanized antibodies. These modifications adjust the biochemical parameters to reduce recognition by the human immune system while preserving the desired immunomodulatory activity against tumor cells.
3Stability of the object's composition
If site-specific amino acid modifications are introduced, then bioactivity and stability are enhanced, but manufacturing complexity increases
Solution Approach 1:
The invention applies segmentation by dividing the antibody structure into specific variable region segments where modifications are introduced. This segmented approach allows for controlled, position-specific modifications rather than global changes, facilitating more manageable manufacturing processes while achieving enhanced stability.
Solution Approach 2:
The patent employs parameter changes through site-specific amino acid substitutions that optimize biochemical properties. These targeted modifications change local structural parameters to enhance stability without requiring complex overall restructuring, thereby limiting the increase in manufacturing complexity.
4Stability of the object's composition
If site-specific amino acid modifications are introduced, then bioactivity and stability are enhanced, but production difficulty increases
Solution Approach 1:
The invention implements local quality by introducing amino acid modifications at specific, predetermined positions in the variable regions. This localized modification strategy simplifies production compared to global modifications, as it allows for targeted changes that can be more easily controlled and validated during manufacturing processes.
Data Source
AI summary
The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.